Adagene Reports Full Year 2023 Financial Results and Provide

- Data for masked anti-CTLA-4 SAFEbody® ADG126 highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable colorectal cancer with higher, more...

Related Keywords

Germany , Australia , Suzhou , Jiangsu , China , Singapore , Japan , United States , German , American , Peter Luo , Zhu Li , Raymond Tam , Adagene Safebody , Asia Pacific , Ulf Grawunder , Mervyn Turner , Yan Li , Andy Yiu Leung Cheung , Linkedin , Audit Committee , Compensation Committee , Dynamic Precision Library , Corporate Governance Committee , Adagene Inc , Nasdaq , Strategy Committee Of The Board , Exchange Commission , Information Technology , Merck Co Inc , European Union , American Society Of Clinical Oncology , Development Rd Expenses , China Center , Twitter , Compensation Committee Of The Board , Merck Sharp Dohme , Clinical Oncology , These Part , Drug Evaluation , Strategy Committee , Yiu Leung , Man Kin , Senior Vice President , Project Optimus , Operating Income , Shares Outstanding , Metastatic Microsatellite Stable , Colorectal Cancer , Merck Sharp , Media Contact , Consolidated Statements , Year Ended December , Markets ,